



WHAT IS CLAIMED IS:

1. A compound of formula:



or a pharmaceutically-acceptable salt thereof.

2. A compound of formula:




3. A pharmaceutical composition comprising the compound of claim 1 or 2, and a pharmaceutically-acceptable carrier.

4. The pharmaceutical composition of claim 3, wherein the composition is suitable for application to the eye.

5. The pharmaceutical composition of claim 4, wherein the composition is suitable for intravitreal injection.


6. The pharmaceutical composition of claim 5, wherein the composition is a suspension.

7. A process for preparing a compound of formula 1




or a pharmaceutically-acceptable salt thereof, the process comprising:

- (a) reacting a compound of formula **6**:




5

with a compound of formula **7-PG**:



wherein R^A is hydroxyl or a leaving group and PG is an amino-protecting group, to give compound **1-PG**:



10

- (b) deprotecting compound **1-PG**; and
 (c) optionally preparing a pharmaceutically-acceptable salt
 to provide a compound of formula **1**, or a pharmaceutically-acceptable salt thereof.

15

8. The process of claim 7, wherein R^A is hydroxyl.

9. The process of claim 8, wherein the reaction between **6** and **7-PG** is conducted in the presence of HATU.

10. The process of claim 7, wherein PG is Boc.

11. The compound as claimed in claim 1 or 2, for use in the treatment of an ocular disease in a mammal.

12. The compound of claim 11, wherein the ocular disease is selected from the group consisting of uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, retinal vein occlusion, and atopic keratoconjunctivitis.

13. The compound of claim 12, wherein the ocular disease is diabetic macular edema or uveitis.

14. Use of the compound as claimed in claim 1 or 2, in the manufacture of a medicament for the treatment of an ocular disease in a mammal.

15. The use of claim 14, wherein the ocular disease is selected from the group consisting of uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, retinal vein occlusion, and atopic keratoconjunctivitis.

16. The use of claim 15, wherein the ocular disease is diabetic macular edema or uveitis.

~~17. — A method of treating an ocular disease in a mammal, the method comprising administering a pharmaceutical composition comprising the compound of claim 1 or 2, and a pharmaceutically acceptable carrier, to the eye of the mammal.~~

~~18. — The method of claim 17, wherein the ocular disease is selected from the group consisting of uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, retinal vein occlusion, and atopic keratoconjunctivitis.~~

19. — ~~The method of claim 18 wherein the ocular disease is diabetic macular edema or uveitis.~~